The Effect of Exercise Training and Detraining on Frailty and Fall Risk in Patients With Chronic Heart Failure

Sponsor
Aristotle University Of Thessaloniki (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06036615
Collaborator
(none)
100
1
2
17.4
5.7

Study Details

Study Description

Brief Summary

Chronic Heart Failure (CHF) is the endpoint for some cardiac and respiratory conditions as well as ageing affecting 1-2% of the global adult population. CHF requires a costly treatment, frequent hospitalizations due its severe complications leading CHF eventually to a frequent cause of morbidity and mortality worldwide. Another common complication of CHF is frailty. Frailty is a complex clinical syndrome associated with CHF, resulting from multiple organ impairment; physiological reserves decrease and vulnerability to stressors increase. Up to 79% of PwCHF are frail leading to reduced functional capacity, quality of life (QoL), and psychological well-being in CHF, and it is an independent predictor of mortality in cardiovascular disease.

The role of cardiac rehabilitation (CR) programs for PwCHF in preventing frailty has recently draw the attention of the scientific world. Exercise constitutes a unique effective and feasible non-pharmacological treatment for frailty in CHF as it offers such benefits that are irreplaceable by medical treatment, with no side effects, and cost-effective treatment. However, there are no studies examining the effect of training and detraining on muscle strength and balance, fall prevention and fear of falling in PwCHF.

The aim of this randomized controlled trial is to examine whether a 6-month combined aerobic, strengthening and flexibility-mobility CR program and a 4-month de-training period will affect frailty and fall risk in PwCHF. Ninety participants will be randomly allocated into two groups: Group A (Exercise Group) will receive 3 sessions per week for 6 months and Group B(Control Group) will continue their usual physical activity, without participating in organized exercise programs.After the intervention for Group A' will follow a 4- month de-training period and Group B' will continue their normal physical activity. Prior to the group random allocation, part of our assessments at baseline and after 6 (Evaluation A') and 10 months (Evaluation B'), will include demographics and clinical history, physical examination, ECG and echocardiogram, patients' ability to perform daily activities, functional tests, static balance tests, body composition analysis and 24-h heart rhytm holter monitoring. Moreover, we will use questionnaires assessing the QoL of people with CHF, depression, anxiety, sleep quality, cognitive function, fear of falling, physical activity, and sedentary behaviour.

Condition or Disease Intervention/Treatment Phase
  • Other: Exercise Intervention
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
The Effect of Exercise Training Intervention and Detraining on Frailty and Fall Risk in Patients With Chronic Heart Failure.
Anticipated Study Start Date :
Oct 1, 2023
Anticipated Primary Completion Date :
Jan 31, 2025
Anticipated Study Completion Date :
Mar 15, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Group A

Exercise Group, 6- month combined aerobic, strengthening, mobiity- flexibility exercise intervention, 4- month de-training period

Other: Exercise Intervention
Patients that will be randomly assigned to this group will be invited to attend up to 72 exercise sessions (3 sessions per week) for 24 weeks (6 months) following a combined aerobic, strengthening and mobility-flexibility exercise program. After the exercise intervention, the will follow a 4-month de-training period, continuing their normal physical activity.

No Intervention: Group B

Control Group, 10- month normal physical activity, without participating in organized sports activities, no intervention

Outcome Measures

Primary Outcome Measures

  1. Left Ventricular Systolic Function [Baseline]

    Evaluation of Left Ventricular Ejection Fraction

  2. Left Ventricular Systolic Function [Evaluation A', 6- months]

    Evaluation of Left Ventricular Ejection Fraction

  3. Left Ventricular Systolic Function [Evaluation B', 4 months after evaluation A']

    Evaluation of Left Ventricular Ejection Fraction

  4. Cardiac Autonomic Nervous System Function [Baseline]

    Evaluation of Cardiac Autonomic Nervous System Function through 24-h Heart Rhythm Holter Monitor measurement

  5. Cardiac Autonomic Nervous System Function [Evaluation A', 6- months]

    Evaluation of Cardiac Autonomic Nervous System Function through 24-h Heart Rhythm Holter Monitor measurement

  6. Cardiac Autonomic Nervous System Function [Evaluation B', 4 months]

    Evaluation of Cardiac Autonomic Nervous System Function through 24-h Heart Rhythm Holter Monitor measurement

  7. Body Composition Analysis [Baseline]

    Evaluation of Body Composition Analysis

  8. Body Composition Analysis [Evaluation A', 6- months]

    Evaluation of Body Composition Analysis

  9. Body Composition Analysis [Evaluation B', 4 months after evaluation A']

    Evaluation of Body Composition Analysis

  10. Six- Minute Walking Test [Baseline]

    Estimation of aerobic capacity through six minutes walking test

  11. Six- Minute Walking Test [Evaluation A', 6- months]

    Estimation of aerobic capacity through six minutes walking test

  12. Six- Minute Walking Test [Evaluation B', 4 months after evaluation A']

    Estimation of aerobic capacity through six minutes walking test

  13. Timed- Up-and-Go Test [Baseline]

    Evaluation of functional capacity using Timed- Up-and-Go Test

  14. Timed- Up-and-Go Test [Evaluation A', 6- months]

    Evaluation of functional capacity using Timed- Up-and-Go Test

  15. Timed- Up-and-Go Test [Evaluation B', 4 months after evaluation A']

    Evaluation of functional capacity and mobility using Timed- Up-and-Go Test

  16. 4m-Walking Test [Baseline]

    Evalution of functional capacity and mobility using 4m-Walking Test

  17. 4m-Walking Test [Evaluation A', 6- months]

    Evalution of functional capacity and mobility using 4m-Walking Test

  18. 4m-Walking Test [Evaluation B', 4 months after evaluation A']

    Evalution of functional capacity and mobility using 4m-Walking Test

  19. 30-second Sit-to-Stand (STS)Test [Baseline]

    Evalution of functional capacity and mobility using 30-second STS

  20. 30-second Sit-to-Stand (STS)Test [Evaluation A', 6- months]

    Evalution of functional capacity and mobility using 30-second STS

  21. 30-second Sit-to-Stand (STS)Test [Evaluation B', 4 months after evaluation A']

    Evalution of functional capacity and mobility using 30-second STS

  22. 5 Sit-to-Stand (5-STS)Test [Baseline]

    Evalution of functional capacity and mobility using 5 Sit-to-Stand

  23. 5 Sit-to-Stand (5-STS)Test [Evaluation A', 6- months]

    Evalution of functional capacity and mobility using 5 Sit-to-Stand

  24. 5 Sit-to-Stand (5-STS)Test [Evaluation B', 4 months after evaluation A']

    Evalution of functional capacity and mobility using 5 Sit-to-Stand

  25. mini-BEST Balance Test [Baseline]

    Evalution of balance using mini-BEST Balance Test

  26. mini-BEST Balance Test [Evaluation A', 6- months]

    Evalution of balance using mini-BEST Balance Test

  27. mini-BEST Balance Test [Evaluation B', 4 months after evaluation A']

    Evalution of balance using mini-BEST Balance Test

  28. Berg Balance Scale Test [Baseline]

    Evalution of balance using Berg Balance Scale Test

  29. Berg Balance Scale Test [Evaluation A', 6- months]

    Evalution of balance using Berg Balance Scale Test

  30. Berg Balance Scale Test [Evaluation B', 4 months after evaluation A']

    Evalution of balance using Berg Balance Scale Test

  31. Functional Gait Assessment Test [Baseline]

    Evalution of Functional Gait using Functional Gait Assessement Test

  32. Functional Gait Assessment Test [Evaluation A', 6- months]

    Evalution of Functional Gait using Functional Gait Assessement Test

  33. Functional Gait Assessment Test [Evaluation B', 4 months after evaluation A']

    Evalution of Functional Gait using Functional Gait Assessement Test

  34. Static Balance Test using 3D Balance Force Plate [Baseline]

    Evalution of Static Balance Test using 3D Balance Force Plate

  35. Static Balance Test using 3D Balance Force Plate [Evaluation A', 6- months]

    Evalution of Static Balance Test using 3D Balance Force Plate

  36. Static Balance Test using 3D Balance Force Plate [Evaluation B', 4 months after evaluation A']

    Evalution of Static Balance Test using 3D Balance Force Plate

  37. Handgrip Strength [Baseline]

    Evaluation of Handgrip Strength

  38. Handgrip Strength [Evaluation A', 6- months]

    Evaluation of Handgrip Strength

  39. Handgrip Strength [Evaluation B', 4 months after evaluation A']

    Evaluation of Handgrip Strength

  40. Isometric Strength of Upper and Lower Extremities [Baseline]

    Evaluation of Isometric Strength of Upper and Lower Extremities

  41. Isometric Strength of Upper and Lower Extremities [Evaluation A', 6- months]

    Evaluation of Isometric Strength of Upper and Lower Extremities

  42. Isometric Strength of Upper and Lower Extremities [Evaluation B', 4 months after evaluation A']

    Evaluation of Isometric Strength of Upper and Lower Extremities

  43. Isometric Pulling in a Semi-Squat Position [Baseline]

    Evaluation of Isometric Pulling in a Semi-Squat Position

  44. Isometric Pulling in a Semi-Squat Position [Evaluation A', 6- months]

    Evaluation of Isometric Pulling in a Semi-Squat Position

  45. Isometric Pulling in a Semi-Squat Position [Evaluation B', 4 months after evaluation A']

    Evaluation of Isometric Pulling in a Semi-Squat Position

  46. 30- second Arm Curl Test [Baseline]

    Evaluation using Arm Curl Test

  47. 30- second Arm Curl Test [Evaluation A', 6- months]

    Evaluation using Arm Curl Test

  48. 30- second Arm Curl Test [Evaluation B', 4 months after evaluation A']

    Evaluation using Arm Curl Test

  49. Sit-and-Reach Test [Baseline]

    Evaluation of mobility-flexibility using Sit-and-Reach Test

  50. Sit-and-Reach Test [Evaluation A', 6- months]

    Evaluation of mobility-flexibility using Sit-and-Reach Test

  51. Sit-and-Reach Test [Evaluation B', 4 months after evaluation A']

    Evaluation of mobility-flexibility using Sit-and-Reach Test

  52. Back Scratch Test [Baseline]

    Evaluation of mobility using Back Scratch Test

  53. Back Scratch Test [Evaluation A', 6- months]

    Evaluation of mobility using Back Scratch Test

  54. Back Scratch Test [Evaluation B', 4 months after evaluation A']

    Evaluation of mobility using Back Scratch Test

  55. SF-36 [Baseline]

    Assessement of Quality of Life using SF-36

  56. SF-36 [Evaluation A', 6- months]

    Assessement of Quality of Life using SF-36

  57. SF-36 [Evaluation B', 4 months after evaluation A']

    Assessement of Quality of Life using SF-36

  58. I-PAQ [Baseline]

    Assessement of Physical Activity using I-PAQ

  59. I-PAQ [Evaluation A', 6- months]

    Assessement of Physical Activity using I-PAQ

  60. I-PAQ [Evaluation B', 4 months after evaluation A']

    Assessement of Physical Activity using I-PAQ

  61. Beck Depression Inventory [Baseline]

    Assessement of Depression using Beck Depression Inventory

  62. Beck Depression Inventory [Evaluation A', 6- months]

    Assessement of Depression using Beck Depression Inventory

  63. Beck Depression Inventory [Evaluation B', 4 months after evaluation A']

    Assessement of Depression using Beck Depression Inventory

  64. Falls Efficacy Scale (FES-I) [Baseline]

    Assessement of fear of falling using Falls Efficacy Scale

  65. Falls Efficacy Scale (FES-I) [Evaluation A', 6- months]

    Evaluation of fear of falling using Falls Efficacy Scale

  66. Falls Efficacy Scale (FES-I) [Evaluation B', 4 months after evaluation A']

    Assessement of fear of falling using Falls Efficacy Scale

  67. Activities-specific Balance Confidence (ABC) Scale [Baseline]

    Assessement of Balance Confidence using ABC

  68. Activities-specific Balance Confidence (ABC) Scale [Evaluation A', 6- months]

    Assessement of Balance Confidence using ABC

  69. Activities-specific Balance Confidence (ABC) Scale [Evaluation B', 4 months after evaluation A']

    Assessement of Balance Confidence using ABC

  70. Minessota Living with Heart Failure (MLHFQ) [Baseline]

    Assessement of health-related quality of life using MLHFQ

  71. Minessota Living with Heart Failure (MLHFQ) [Evaluation A', 6- months]

    Assessement of health-related quality of life using MLHFQ

  72. Minessota Living with Heart Failure (MLHFQ) [Evaluation B', 4 months after evaluation A']

    Assessement of health-related quality of life using MLHFQ

  73. Pittsburgh Sleep Quality Index (PSQI) [Baseline]

    Assessement of Sleep Quality using PSQI

  74. Pittsburgh Sleep Quality Index (PSQI) [Evaluation A', 6- months]

    Assessement of Sleep Quality using PSQI

  75. Pittsburgh Sleep Quality Index (PSQI) [Evaluation B', 4 months after evaluation A']

    Assessement of Sleep Quality using PSQI

  76. Intrinsic Motivation Inventory (IMI) [Baseline]

    Assessement of Intrinsic Motivation using IMI

  77. Intrinsic Motivation Inventory (IMI) [Evaluation A', 6- months]

    Assessement of Intrinsic Motivation using IMI

  78. Intrinsic Motivation Inventory (IMI) [Evaluation B', 4 months after evaluation A']

    Assessement of Intrinsic Motivation using IMI

  79. Hamilton Rating Scale for Depression (HRSD) and Hamilton Anxiety Rating Scale (HARS) [Baseline]

    Assessement of Depression and Anxiety using HRSD and HARS

  80. Hamilton Rating Scale for Depression (HRSD) and Hamilton Anxiety Rating Scale (HARS) [Evaluation A', 6- months]

    Assessement of Depression and Anxiety using HRSD and HARS

  81. Hamilton Rating Scale for Depression (HRSD) and Hamilton Anxiety Rating Scale (HARS) [Evaluation B', 4 months after evaluation A']

    Assessement of Depression and Anxiety using HRSD and HARS

  82. Montreal Cognitive Assessment Test (MOCA) [Baseline]

    Assessement of cognitive function using MOCA

  83. Montreal Cognitive Assessment Test (MOCA) [Evaluation A', 6- months]

    Assessement of cognitive function using MOCA

  84. Montreal Cognitive Assessment Test (MOCA) [Evaluation B', 4 months after evaluation A']

    Assessement of cognitive function using MOCA

  85. Falls [Baseline]

    Assessement of the number of weekly falls

  86. Falls [Evaluation A', 6- months]

    Assessement of the number of weekly falls

  87. Falls [Evaluation B', 4 months after evaluation A']

    Assessement of the number of weekly falls

  88. Evaluation of Physical Activity and Sleep Quality using a wearable device [Baseline]

    Evaluation of Physical Activity and Sleep Quality using a wearable device

  89. Evaluation of Physical Activity and Sleep Quality using a wearable device [Evaluation A', 6- months]

    Evaluation of Physical Activity and Sleep Quality using a wearable device

  90. Evaluation of Physical Activity and Sleep Quality using a wearable device [Evaluation B', 4 months after evaluation A']

    Evaluation of Physical Activity and Sleep Quality using a wearable device

  91. Foot Preferance Questionnaire (FPQ) [Baseline]

    Assessement of Foot Preference during static balance or activities using FPQ

  92. Foot Preferance Questionnaire (FPQ) [Evaluation A', 6- months]

    Assessement of Foot Preference during static balance or activities using FPQ

  93. Foot Preferance Questionnaire (FPQ) [Evaluation B', 4 months after evaluation A']

    Assessement of Foot Preference during static balance or activities using FPQ

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 100 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age > 18 yrs. of either gender

  • Confirmed diagnosis (by echocardiography) of HF reduced or preserved left ventricular ejection fraction (HFrEF/ΗFpEF)

  • Symptomatic New York Heart Association (NYHA) class II-III

Exclusion Criteria:
  • Acute Myocardial Infarction (<4 weeks)

  • Severe valvular diseases

  • Potentially malignant arrhythmias

  • Νeurological, or orthopedic limitations/non- ambulant status

  • Cognitive disorders

  • Poor regulation of comorbidities

  • Already participating in organized exercise programs

  • Current pregnancy

  • NYHA function class IV

  • Inability/unwillingness to give informed consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sports Medicine Laboratory, Aristotle University of Thessaloniki Thessaloniki Thermi Greece 57001

Sponsors and Collaborators

  • Aristotle University Of Thessaloniki

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Evangelia Kouidi, Professor of Sports Medicine, Aristotle University Of Thessaloniki
ClinicalTrials.gov Identifier:
NCT06036615
Other Study ID Numbers:
  • 110/2022
First Posted:
Sep 14, 2023
Last Update Posted:
Sep 14, 2023
Last Verified:
Sep 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Evangelia Kouidi, Professor of Sports Medicine, Aristotle University Of Thessaloniki
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 14, 2023